These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 17434105

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
    Orio P, Wallner K, Merrick G, Herstein A, Mitsuyama P, Thornton K, Butler W, Sutlief S.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):342-6. PubMed ID: 17236959
    [Abstract] [Full Text] [Related]

  • 23. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L, Huang D, Fearn P, Kattan MW.
    Brachytherapy; 2003 Feb 01; 2(1):26-31. PubMed ID: 15062160
    [Abstract] [Full Text] [Related]

  • 24. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR.
    Urology; 2007 Jul 01; 70(1):106-10. PubMed ID: 17656218
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
    Eggener SE, Roehl KA, Yossepowitch O, Catalona WJ.
    J Urol; 2006 Oct 01; 176(4 Pt 1):1399-403. PubMed ID: 16952643
    [Abstract] [Full Text] [Related]

  • 27. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2006 Jan 01; 64(1):136-43. PubMed ID: 16198062
    [Abstract] [Full Text] [Related]

  • 28. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 29. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
    D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH.
    J Urol; 2003 Apr 15; 169(4):1320-4. PubMed ID: 12629352
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
    Wallner K, Merrick G, True L, Sherertz T, Sutlief S, Cavanagh W, Butler W.
    Radiother Oncol; 2005 Jun 15; 75(3):307-10. PubMed ID: 16086912
    [Abstract] [Full Text] [Related]

  • 33. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
    Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P.
    Urol Oncol; 2006 Jun 15; 24(5):396-402. PubMed ID: 16962488
    [Abstract] [Full Text] [Related]

  • 34. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone.
    Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR.
    Am J Clin Oncol; 2007 Apr 15; 30(2):199-204. PubMed ID: 17414471
    [Abstract] [Full Text] [Related]

  • 35. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF, Skoglund S, Galbreath RW, Merrick G.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):57-64. PubMed ID: 17084544
    [Abstract] [Full Text] [Related]

  • 36. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
    Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR, CaPSURE Investigators.
    J Urol; 2004 Apr 01; 171(4):1393-401. PubMed ID: 15017184
    [Abstract] [Full Text] [Related]

  • 37. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM, Porter MP, Soloway MS.
    J Urol; 2008 Nov 01; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [Abstract] [Full Text] [Related]

  • 38. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
    Peters CA, Stock RG, Blacksburg SR, Stone NN.
    Int J Radiat Oncol Biol Phys; 2009 Jan 01; 73(1):24-9. PubMed ID: 18692325
    [Abstract] [Full Text] [Related]

  • 39. Predictors of metastatic disease after prostate brachytherapy.
    Forsythe K, Burri R, Stone N, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):645-52. PubMed ID: 22137025
    [Abstract] [Full Text] [Related]

  • 40. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
    Chen RC, Sadetsky N, Chen MH, Carroll PR, D'Amico AV.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):36-9. PubMed ID: 19233568
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.